In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation.<h4>Case presentation</h4>A 44-year-old female had previously undergone surgery for resection of a malignant melanoma in the lower right leg. The gene discussed is BRAF; the disease is metastatic melanoma.